164 related articles for article (PubMed ID: 21525187)
21. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
[TBL] [Abstract][Full Text] [Related]
22. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.
McDaniel AS; Allen JD; Park SJ; Jaffer ZM; Michels EG; Burgin SJ; Chen S; Bessler WK; Hofmann C; Ingram DA; Chernoff J; Clapp DW
Blood; 2008 Dec; 112(12):4646-54. PubMed ID: 18768391
[TBL] [Abstract][Full Text] [Related]
23. Occult neurofibroma and increased S100 protein in the skin of patients with neurofibromatosis type 1: new insight to the etiopathomechanism of neurofibromas.
Karvonen SL; Kallioinen M; Ylä-Outinen H; Pöyhönen M; Oikarinen A; Peltonen J
Arch Dermatol; 2000 Oct; 136(10):1207-9. PubMed ID: 11030766
[TBL] [Abstract][Full Text] [Related]
24. Mast cells and the neurofibroma microenvironment.
Staser K; Yang FC; Clapp DW
Blood; 2010 Jul; 116(2):157-64. PubMed ID: 20233971
[TBL] [Abstract][Full Text] [Related]
25. Ketotifen suppression of NF1 neurofibroma growth over 30 years.
Riccardi VM
Am J Med Genet A; 2015 Jul; 167(7):1570-7. PubMed ID: 25974154
[TBL] [Abstract][Full Text] [Related]
26. The presence and progression of choroidal neurofibromas in a predominantly pediatric population with neurofibromatosis type-1.
Chilibeck CM; Shah S; Russell HC; Vincent AL
Ophthalmic Genet; 2021 Jun; 42(3):223-229. PubMed ID: 33594930
[No Abstract] [Full Text] [Related]
27. Clinical and Sonographic Classification of Neurofibromas in Children with Neurofibromatosis Type 1 - A Cluster Analysis.
García-Martínez FJ; Alfageme F; Duat-Rodríguez A; Andrés Esteban EM; Hernández-Martín A
Ultraschall Med; 2023 Apr; 44(2):e118-e125. PubMed ID: 34820795
[TBL] [Abstract][Full Text] [Related]
28. Vessel and Mast Cell Densities in Sporadic and Syndrome-associated Peripheral Nerve Sheath Tumors.
Friedrich RE; Naber U; Glatzel M; Hagel C
Anticancer Res; 2015 Sep; 35(9):4713-22. PubMed ID: 26254361
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics predicting internal neurofibromas in 357 children with neurofibromatosis-1: results from a cross-selectional study.
Sbidian E; Hadj-Rabia S; Riccardi VM; Valeyrie-Allanore LL; Barbarot S; Chosidow O; Ferkal S; Rodriguez D; Wolkenstein P; Bastuji-Garin S
Orphanet J Rare Dis; 2012 Sep; 7():62. PubMed ID: 22943186
[TBL] [Abstract][Full Text] [Related]
30. Ki-67 proliferation-index (MIB-1) of neurofibromas in neurofibromatosis type 1 patients.
Friedrich RE; Hagel C; Brehme Z; Kluwe L; Mautner VF
Anticancer Res; 2003; 23(2A):953-5. PubMed ID: 12820329
[TBL] [Abstract][Full Text] [Related]
31. [Neurinomas-neurofibromas].
Goujon JM; Bataille B; Menet E; Lapierre F
Neurochirurgie; 1997; 43(1):35-8. PubMed ID: 9205625
[TBL] [Abstract][Full Text] [Related]
32. Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of
Burks CA; Rhodes SD; Bessler WK; Chen S; Smith A; Gehlhausen JR; Hawley ET; Jiang L; Li X; Yuan J; Lu Q; Jacobsen M; Sandusky GE; Jones DR; Clapp DW; Blakeley JO
Mol Cancer Ther; 2019 Dec; 18(12):2321-2330. PubMed ID: 31527226
[TBL] [Abstract][Full Text] [Related]
33. Angiogenic and invasive properties of neurofibroma Schwann cells.
Sheela S; Riccardi VM; Ratner N
J Cell Biol; 1990 Aug; 111(2):645-53. PubMed ID: 1696266
[TBL] [Abstract][Full Text] [Related]
34. Vascular Innervation in Benign Neurofibromas of Patients with Neurofibromatosis Type 1.
Friedrich RE; Behrendt CA; Glatzel M; Hagel C
Anticancer Res; 2015 Dec; 35(12):6509-16. PubMed ID: 26637864
[TBL] [Abstract][Full Text] [Related]
35. Mast cell and lymphoreticular infiltrates in neurofibromas. Comparison with nerve sheath tumors.
Johnson MD; Kamso-Pratt J; Federspiel CF; Whetsell WO
Arch Pathol Lab Med; 1989 Nov; 113(11):1263-70. PubMed ID: 2479359
[TBL] [Abstract][Full Text] [Related]
36. Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study.
Friedrich RE; Nörnberg LKN; Hagel C
Anticancer Res; 2022 Mar; 42(3):1247-1261. PubMed ID: 35220215
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous neurofibromas: Current clinical and pathologic issues.
Ortonne N; Wolkenstein P; Blakeley JO; Korf B; Plotkin SR; Riccardi VM; Miller DC; Huson S; Peltonen J; Rosenberg A; Carroll SL; Verma SK; Mautner V; Upadhyaya M; Stemmer-Rachamimov A
Neurology; 2018 Jul; 91(2 Suppl 1):S5-S13. PubMed ID: 29987130
[TBL] [Abstract][Full Text] [Related]
38. Identification of growth hormone receptor in localised neurofibromas of patients with neurofibromatosis type 1.
Cunha KS; Barboza EP; Da Fonseca EC
J Clin Pathol; 2003 Oct; 56(10):758-63. PubMed ID: 14514779
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Sirén V; Peltonen J; Vaheri A
Arch Dermatol Res; 2006 Mar; 297(9):421-4. PubMed ID: 16408192
[TBL] [Abstract][Full Text] [Related]
40. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells.
Yang FC; Ingram DA; Chen S; Hingtgen CM; Ratner N; Monk KR; Clegg T; White H; Mead L; Wenning MJ; Williams DA; Kapur R; Atkinson SJ; Clapp DW
J Clin Invest; 2003 Dec; 112(12):1851-61. PubMed ID: 14679180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
